Clinical trials: TACE, completed
Hepatocellular Carcinoma (HCC)
IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)
This is a multicenter, single arm, prospective, open-label phase II trial investigating the clinical activity of peri-interventional treatment with the anti-PD1 antibody pembrolizumab in HCC patients who are candidates for local…
- Trial name
- NCT03753659
- Testing
- Pembrolizumab, Radio Frequency Ablation (RFA), Microwave Ablation (MWA)
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Primary Liver Carcinoma
Study of Pembrolizumab Following TACE in Primary Liver Carcinoma
Open label, single arm, multi-centre study of pembrolizumab following trans-arterial chemoembolization (TACE). Twenty-six to 32 evaluable participants with primary liver cancer (hepatocellular cancer; HCC) will be assessed.
- Trial name
- PETAL (NCT03397654)
- Testing
- Pembrolizumab, Trans-arterial chemoembolization
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- Imperial College London
Cancer, Hepatocellular
A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer
The purpose of this study is to evaluate the safety and tolerability of nivolumab with and without ipilimumab in combination with Trans-arterial ChemoEmbolization (TACE) to TACE alone in participants with intermediate liver…
- Trial name
- CheckMate 74W (NCT04340193)
- Testing
- nivolumab, ipilimumab, TACE
- Where
- 107 sites in United States, Australia and 17 more
- Volunteers
- 26 people
- Sponsor
- Bristol-Myers Squibb
Hepatocellular Carcinoma
Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC
Hepatocellular carcinoma (HCC) is a common disease with high mortality. More than 80% patients receive a diagnosis when their tumors are too advanced for curative approaches and have a dismal prognosis.
- Trial name
- NCT04011033
- Testing
- iNKT cells, Human recombinated Interleukin-2, TAE/TACE
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing YouAn Hospital
Carcinoma, Hepatocellular
Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma
Patients with liver tumor burden that exceeds Milan criteria are considered to receive one of the following locoregional treatments: transarterial chemoembolization (TACE), radiofrequency ablation (RFA), percutaneous ethanol…
- Trial name
- NCT00857805
- Testing
- Transarterial Chemoembolization, Proton Beam Radiotherapy
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Loma Linda University
Hepatocellular Carcinoma, HCC
Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) as Bridge to Liver Transplant
This study will compare stereotactic body radiation therapy (SBRT) to trans-arterial chemoembolization (TACE) as a bridging strategy for patients with HCC undergoing orthotopic liver transplantation.
- Trial name
- SBRTvsTACE (NCT02182687)
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Trans-Arterial Chemoembolization (TACE), Doxorubin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Lahey Clinic
Liver Cancer, Metastatic Cancer
Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
RATIONALE: Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor.
- Trial name
- NCT00003907
- Testing
- cisplatin, doxorubicin, mitomycin
- Where
- 37 sites in United States
- Volunteers
- 50 people
- Sponsor
- Eastern Cooperative Oncology Group
Hepatocellular Carcinoma
Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma
The purpose of this study is to develop better ways to treat liver cancer, known as hepatocellular carcinoma or HCC, while it is still in the liver.
- Trial name
- NCT02513199
- Testing
- SBRT, TACE
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Biliary Tract Neoplasms, Liver Cancer
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
BACKGROUND: Various tumor ablative procedures and techniques have been shown to result in immunogenic cell death and induction of a peripheral immune response.
- Conditions
- Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma
- Trial name
- NCT02821754
- Testing
- Durvalumab, Tremelimumab, Trans-arterial Catheter Chemoembolization (TACE)
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer
Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery
RATIONALE: Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor.
- Trial name
- NCT00956930
- Testing
- yttrium Y 90 glass microspheres, Doxorubicin
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Northwestern University
Hepatocellular Carcinoma, Hepatoma
Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma
This study will combine two therapies to treat patients with unresectable hepatocellular carcinoma; sorafenib, and drug eluting beads delivered intra-arterially.
- Trial name
- NCT00844883
- Testing
- sorafenib, LC Bead-TACE
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Yale University
Colon Cancer With Metastases to the Liver
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab
This is a multicentre, open labeled, controlled phase study designed to assess effectiveness of chemoembolization with LC Beads, both with and without systemic chemotherapy, in the treatment of unresectable liver metastases in…
- Trial name
- DEBIRI (NCT00932438)
- Testing
- LC beads loaded with Irinotecan, Oxaliplatin, Leucovorin
- Where
- 10 sites in United States, Argentina
- Volunteers
- 70 people
- Sponsor
- University of Louisville
Hepatocellular Carcinoma
Prospective Study to Evaluate Safety of Deb-TACE With 100µ Beads in Patients With Non Resectable HCC
This is an observational, multicenter, single arm, prospective study to evaluate safety and tolerability of selective and ultraselective drug eluting beads transcatheter intraarterial chemoembolization (DEB-TACE) with up to 3 ml…
- Trial name
- NCT02670122
- Testing
- DEB-TACE
- Where
- Spain
- Volunteers
- 131 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
HepatoCellular Carcinoma
Efficacy and Safety of Drug Eluting Beads TACE in Treatment of HCC in Egyptian Patients
This study aimed to to compare the conventional transarterial chemoembolization (cTACE) with chemoembolization using doxorubicin drug eluting beads (DEB-TACE) for the treatment of hepatocellular carcinoma regarding short term…
- Trial name
- NCT03007225
- Testing
- Trans-arterial chemoembolization (TACE), TACE with Drug Eluting Beads procedure
- Volunteers
- 50 people
- Sponsor
- Ain Shams University
Hepatocellular Carcinoma, Malignant Neoplasm
Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection
The purpose of this study is to assess the efficacy and safety of combining autologous Tcm immunotherapy and TACE in HCC patients with MVI after radical resection.
- Trial name
- NCT03575806
- Testing
- TACE plus autologous Tcm immunotherapy, TACE
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Heptocellular Cancer, Biliary Tract Neoplasms
Tremelimumab With Chemoembolization or Ablation for Liver Cancer
Background: Tremelimumab is a cancer treatment drug that helps the immune system recognize and destroy cancer cells. Researchers want to see if it can be used to treat advanced liver cancer.
- Conditions
- Heptocellular Cancer, Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma
- Trial name
- NCT01853618
- Testing
- Tremelimumab, RFA, TACE
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer
Purpose: The purpose of this study is to determine the feasibility and safety of using small beads (70-150 micron in place of 100-300 micron) to deliver chemotherapy into the liver to treat patients with liver lesions from…
- Trial name
- NCT02015754
- Testing
- DEBIRI, LC Bead M1, TACE
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Yale University
Hepatocellular Carcinoma (HCC)
A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma
This investigational study will evaluate if using a combination of TACE along with high dose SBRT would show improvement in local control in patients with Hepatocellular Carcinoma.
- Trial name
- RAD 0902 (NCT01247298)
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Alabama at Birmingham
Liver Cancer
A Study of Avastin (Bevacizumab) and Transarterial Chemoembolisation (TACE) Treatment in Patients With Liver Cancer
This single-arm, open-label study assessed the efficacy and safety of Avastin (bevacizumab) treatment combined with transarterial chemoembolisation (TACE) in patients with localized unresectable liver cancer.
- Trial name
- NCT00576199
- Testing
- Bevacizumab, Transarterial chemoembolisation (TACE)
- Where
- 3 sites in Hong Kong
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche